Trial on Refinement of Early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: The TREAT protocol by Kreuter, Michael et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Cancer
Open Access Study protocol
Trial on Refinement of Early stage non-small cell lung cancer. 
Adjuvant chemotherapy with pemetrexed and cisplatin versus 
vinorelbine and cisplatin: The TREAT protocol
Michael Kreuter1, Johan Vansteenkiste2, Frank Griesinger3, Hans Hoffmann4, 
Hendrik Dienemann4, Paul De Leyn5 and Michael Thomas*1
Address: 1Department of Medicine/Thoracic Oncology, Thoraxklinik at the University of Heidelberg, Amalienstr. 5, 69126 Heidelberg, Germany, 
2Department of Pulmonology, University Hospital and Leuven Lung Cancer Group, Herestraat 49, 3000 Leuven, Belgium, 3Department of 
Oncology, Piushospital Oldenburg, Georgstraße 12, 26121 Oldenburg, Germany, 4Department of Thoracic Surgery, Thoraxklinik at the University 
of Heidelberg, Amalienstr. 5, 69126 Heidelberg, Germany and 5Department of Thoracic Surgery, University Hospital and Leuven Lung Cancer 
Group, Herestraat 49, 3000 Leuven, Belgium
Email: Michael Kreuter - michael.kreuter@thoraxklinik-heidelberg.de; Johan Vansteenkiste - johan.vansteenkiste@uz.kuleuven.ac.be; 
Frank Griesinger - fgriesi@gwdg.de; Hans Hoffmann - hans.hoffmann@thoraxklinik-heidelberg.de; 
Hendrik Dienemann - hendrik.dienemann@thoraxklinik-heidelberg.de; Paul De Leyn - paul.deleyn@uz.kuleuven.ac.be; 
Michael Thomas* - michael.thomas@thoraxklinik-heidelberg.de
* Corresponding author    
Abstract
Background: Adjuvant chemotherapy has been proven to be beneficial for patients with early
stage non-small cell lung cancer. However, toxicity and insufficient dose delivery have been critical
issues with the chemotherapy used. Doublet regimens with pemetrexed, a multi-target folate
inhibitor, and platin show clear activity in non-small cell lung cancer and are well tolerated with low
toxicity rates and excellent delivery.
Methods/Design: In this prospective, multi-center, open label randomized phase II study, patients
with pathologically confirmed non-small cell lung cancer, stage IB, IIA, IIB, T3N1 will be randomized
after complete tumor resection either to 4 cycles of the standard adjuvant vinorelbine and cisplatin
regimen from the published phase III data, or to 4 cycles of pemetrexed 500 mg/m2 d1 and cisplatin
75 mg/m2 d1, q 3 weeks. Primary objective is to compare the clinical feasibility of these cisplatin
doublets defined as non-occurrence of grade 4 neutropenia and/or thrombocytopenia > 7 days or
bleeding, grade 3/4 febrile neutropenia and/or infection, grade 3/4 non-hematological toxicity, non-
acceptance leading to premature withdrawal and no cancer or therapy related death. Secondary
parameters are efficacy (time to relapse, overall survival) and drug delivery. Parameters of safety
are hematologic and non-hematologic toxicity of both arms.
Discussion: The TREAT trial was designed to evaluate the clinical feasibility, i.e. rate of patients
without dose limiting toxicities or premature treatment withdrawal or death of the combination
of cisplatin and pemetrexed as well as the published phase III regimen of cisplatin and vinorelbine.
Hypothesis of the study is that reduced toxicities might improve the feasibility of drug delivery,
compliance and the convenience of treatment for the patient and perhaps survival.
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Background
Non-small cell lung cancer (NSCLC) accounts for the larg-
est number of cancer deaths annually, worldwide [1]. Of
these, about 30 % are early stage patients (stage I and II).
For this group of patients, radical surgery with mediastinal
lymph node dissection has been the mainstay of therapy
with a reasonable curative option. However, 5-year sur-
vival rates for patients with pathologically staged IA-IIB
disease are ranging from 67% to 39% [2]. Following sur-
gery, distant recurrence is the most common form of
relapse and eventual cause of death. Assuming that these
recurrences are due to occult micrometastases at the time
of surgery, trials on adjuvant systemic therapy have been
performed in an attempt to reduce the risk of recurrence
and to improve survival. Historically, early randomized
trials of postoperative chemotherapy failed to demon-
strate a consistent benefit. A meta-analysis of randomized
trials compared surgery alone with additional chemother-
apy in stage I-IIIA NSCLC suggesting an absolute survival
benefit of 5% at 5 years for cisplatin-containing chemo-
therapy regimens. However, statistical significance was
not reached (overall hazard-ratio (HR) of 0.87, p = 0.08)
[3]. This finding prompted renewed interest in studying
the beneficial effect of adjuvant chemotherapy in NSCLC.
In some of the recently published trials a clear benefit of
adjuvant chemotherapy in early stage NSCLC could not
be achieved [4-6]. In marked contrast to these studies,
three recent, big randomized trials on early stage NSCLC
patients with modern platin-based two-drug chemother-
apy-regimens revealed a significant advantage for overall
or relapse free survival for chemotherapeutically treated
patients [7-9]. The majority of patients in the adjuvant
treatment setting received a combination of cisplatin and
vinorelbine. A pooled analysis of five big randomized
studies demonstrated that adjuvant cisplatin-based chem-
otherapy improves survival in patients with NSCLC signif-
icantly (overall HR of death 0,89, p < 0,005)
corresponding to a survival benefit of 4.2% for all stages
[10]. However, toxicity and inadequate dose delivery have
been critical issues in all trials performed so far. Grade 3/
4 toxicities are observed up to 73% [11] with rates of neu-
tropenic fever up to 7% [8]. Up to 77% of the patients had
at least one dose reduction or omission and 55% required
one dose delay or more, most related to neutropenia.
Only about 50% of patients randomized on the combina-
tion of cisplatin and vinorelbine received the intended
dose of vinorelbine and only 50% of patients completed
all four cycles of chemotherapy [8,9,12]. Reasons for dis-
continuation of chemotherapy were mainly patient
refusal combined with toxicity while disease progression
or intercurrent illness were uncommon reasons [12].
Pemetrexed, a multi-target folate antimetabolite, shows
clear activity in non-small cell lung cancer. In a phase III
study [13] for patients with previously treated advanced
non-small cell lung cancer, the efficacy of single-agent
pemetrexed, as determined by overall survival, was similar
to that of docetaxel. Results from Phase II studies have
shown that the efficacy of a platinum based combination
therapy with pemetrexed is similar to other standard plat-
inum doublets, with response rates of 27% to 45% and
median survivals of 8.9 to 10.9 months [14-18]. This dou-
blet can be delivered easily and is well tolerated. Further-
more, it results in a 25% rate of grade 3/4 neutropenia
only and the incidence of febrile neutropenia was < 1% in
vitamin supplemented patients. Dose reductions occur
only in 2–4% of the patients and dose delivery is excellent
with delivery rates of pemetrexed up to 95% [13,14,19].
Therefore, it seems reasonable to test a less toxic regimen
also in early stages after complete (R0) resection of the
tumor, where reduced toxicities might improve the feasi-
bility of drug delivery, compliance and the convenience of
treatment for the patient and hence perhaps survival.
The main purpose of this randomized phase II trial, the
TREAT protocol, is to evaluate the clinical feasibility – in
terms of patients without dose limiting toxicities or pre-
mature treatment withdrawal or death – of the combina-
tion of cisplatin and pemetrexed as well as the
combination of cisplatin and vinorelbine.
Methods/Design
Trial organization
TREAT has been designed by the AIO Lung Cancer Study
Group, Germany and the LLCG Leuven Lung Cancer
Group, Belgium under responsibility of the Clinic for tho-
racic diseases at the University of Heidelberg, Germany.
The trial is an investigator initiated trial.
Coordination
The trial is coordinated by the Department of Medicine/
Thoracic Oncology, Clinic for thoracic diseases at the Uni-
versity of Heidelberg, Germany in cooperation with the
Respiratory Oncology Unit (Pulmonology) and Leuven
Lung Cancer Group, Catholic University, Leuven, Belgium
and the Department of Hematology and Oncology, Uni-
versity of Goettingen, Germany. The Department of Med-
icine/Thoracic Oncology, Clinic for thoracic diseases at
the University of Heidelberg is responsible for overall trial
management, trial registration (ClinicalTrials.gov Identi-
fier: NCT00349089, EudraCT Number 2005-004840-30),
database management, quality assurance including mon-
itoring, reporting and for the scientific program of all trial
related meetings supported by Ingenix Pharmaceutical
Services (Deutschland) GmbH/i3 research | SKM Oncol-
ogy, Germany.BMC Cancer 2007, 7:77 http://www.biomedcentral.com/1471-2407/7/77
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Investigators
Patients will be recruited in the following centers: Ger-
many: Departments of Medicine/Thoracic Oncology and
of Thoracic Surgery, Thoraxklinik at the University of Hei-
delberg; Departments of Hematology and Oncology and
of Thoracic and Cardiovascular Surgery, University of
Goettingen; Department of Medicine/Thoracic Oncology
Klinik Löwenstein, Löwenstein; Departments of Medi-
cine/Thoracic Oncology and of Thoracic Surgery, Helios-
Klinikum Emil von Behring, Berlin; Departments of Med-
icine/Pneumology and of Thoracic Surgery, Klinikum
Bremen-Ost, Bremen; Westdeutsches Tumorzentrum,
Essen; Departments of Medicine/Hematology and Oncol-
ogy and of Thoracic Surgery, Dr. Horst Schmidt Klinik,
Wiesbaden; Department of Medicine/Pneumology, Klini-
kum der Universität München; Departments of Medicine/
Thoracic Oncology and of Thoracic Surgery, Lungenzen-
trum Großhansdorf, Großhansdorf; Departments of Med-
icine/Pneumology and of Thoracic Surgery, Lungenklinik
Hemer, Hemer; Belgium: Department of Pulmonology
(Respiratory Oncology Unit), University Hospital
Gasthuisberg, Leuven, Department of Pneumology,
Ziekenhuis Oost Limburg, Genk; Department of Pneu-
mology, CHU Sart Tilman, Liege, Department of Thoracic
Surgery, University Hospital and Leuven Lung Cancer
Group, Leuven, Luxembourg: Departments of Hematology-
Oncology and of Thoracic Surgery, Centre Hospitalier
Luxembourg, Luxembourg. All investigators are experi-
enced oncologists in the field of medical und thoracic
oncology.
Adverse events committee
This committee consists of 2 independent physicians
(medical oncologist) and decides on the final diagnostic
classification of critical clinical events. For all serious
adverse events the documentation and relevant patient
data are verified by the coordinating personnel before
submitting the data to the Adverse Events Committee for
diagnostic classification.
Analysis of safety related data is performed with respect to
frequency of:
￿ Serious Adverse Events and Adverse Events stratified by
organ-system
￿ Adverse Events stratified by severity
￿ Adverse Events stratified by causality.
Patient toxicities will be assessed using the NCI Common
Toxicity Criteria [27].
A serious adverse event is defined as an AE occurring dur-
ing any study phase and at any dose of the investigational
product that fulfils one or more of the following criteria:
￿ results in death
￿ is immediately life-threatening
￿ requires in-subject hospitalization or prolongation of
existing hospitalization
￿ results in persistent or severe disability, incapacity or
cancer (other than the cancer diagnosed prior to enrol-
ment in the study)
￿ is a congenital abnormality or birth defect
￿ is an important medical event that may jeopardize the
subject or may require medical intervention to prevent
one of the outcomes listed above
￿ or is significant for any other reason
Any serious adverse event experienced by the patient
which might be related to the study drugs will be reported
by the CRO to the sponsor, to Eli Lilly and Company for
pemetrexed and to Medac GmbH for vinorelbine and for
cisplatin. In addition, adverse events will be reported to
regulatory authorities according to the definitions and
timelines specified in the local laws and regulations. The
Serious Adverse Event must be followed up until resolu-
tion, follow-up documentation has to be provided by the
center.
On-site monitoring
During recruitment of patients monitoring on site is per-
formed according to good clinical practice (GCP) guide-
lines. The data management will be performed by Ingenix
Pharmaceutical Services (Deutschland) GmbH/i3
research | SKM Oncology, Germany.
Ethics, informed consent and safety
The final protocol was approved by the ethics committee
of the University of Heidelberg, Germany [] and the Bun-
desinstitut für Arzneimittel und Medizinprodukte
(BfArM-registration number 4031656). This study com-
plies with the Helsinki Declaration in its recent German
version, the Medical Association's professional code of
conduct, the principles of Good Clinical Practice (GCP)
guidelines and the Federal Data Protection Act. The trial
will also be carried out in keeping with local legal and reg-
ulatory requirements. The medical secrecy and the Federal
Data Protection Act will be followed.BMC Cancer 2007, 7:77 http://www.biomedcentral.com/1471-2407/7/77
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Written informed consent is obtained from each patient
in oral and written form before inclusion in the trial and
the nature, scope, and possible consequences of the trial
have been explained by a physician. The investigator will
not undertake any measures specifically required only for
the clinical trial until valid consent has been obtained.
Study design
The TREAT study is a prospective, multi-center, open
label, randomized phase II study determining the clinical
feasibility in terms of toxicity of 4 cycles of adjuvant
chemotherapy with pemetrexed and cisplatin versus
vinorelbine and cisplatin in patients with non-small lung
cancer stage IB, IIA, IIB and T3N1 (without need for fur-
ther radiotherapy).
Randomization will be balanced between treatment arms
according to the following factors:
￿ Center
￿ Nodal Status (N0 vs. N1)
￿ Surgical procedure (lobectomy vs. pneumonectomy)
The primary objective is to determine the clinical feasibil-
ity rate (CFR) of 4 cycles of adjuvant chemotherapy with
Pemetrexed and Cisplatin vs. Vinorelbine and Cisplatin in
patients with NSCLC stage IB, IIA, IIB and T3N1 (without
need for further radiotherapy). Treatment is considered to
have clinical feasibility if dose limiting toxicity (DLT) will
not be observed, and no non-acceptance by the patient
leading to premature withdrawal, and no death due to
cancer or cancer therapy will occur. DLTs are defined as:
￿ Grade 4 neutropenia more than 7 days
￿ Grade 4 thrombocytopenia more than 7 days
￿ Grade 3/4 neutropenia with fever (i.e. > 38.5°C on at
least 2 occasions in 24 hours time) and/or infection (i.e.
documented by either culture or imaging method)
￿ Any grade thrombocytopenia with bleeding
￿ Grade 3/4 non-hematological toxicity possibly or prob-
ably related to the chemotherapy (except for nausea/vom-
iting/hair loss)
Secondary objectives are to determine and compare the
drug delivery between both treatment arms, the time to
treatment failure, the relapse free survival, the overall sur-
vival, the distant metastases free survival, local relapse free
survival, the localization of relapse, the dose delivery, and
safety.
Statistical design
This phase II trial design is based on the following
assumptions: the experimental therapy arm would be
rated as unacceptable, if the actual feasibility rate (= 1 –
withdrawal/DLT rate) was 65 % or lower. On the other
hand, the therapy would be considered to be a promising
candidate for further development, if the true feasibility
rate amounted to 80% or more. Probability to accept the
experimental therapy as well tolerable, in spite of a true
feasibility rate of < 65% (i.e. withdrawal/DLT rate > 35%):
5% (type I error). Probability to reject the experimental
therapy as not sufficiently feasible (< 65%), although the
true feasibility rate is promising (> 80%): 20% (type II
error, corresponding to a power of 80%). According to
these parameters, and using the variant out of the class of
optimal two-stage designs by Simon [20] that leads to the
lowest maximum number of patients required (minimax
approach), n = 18 patients evaluable for feasibility have
to be recruited in the first stage. The combination will be
rejected, if three or more of these patients fulfil the crite-
rion of non-feasibility. In the second step, further patients
will be recruited up to a total number of 67 cases. The
final conclusion of the trial will depend on the definite
feasibility rate (and its confidence interval), the respective
findings in the vinorelbine/cisplatin reference arm, the
achieved level of drug delivery as well as the complete
information on type, frequency and severity of toxicities.
As a similar number of patients is to be recruited to the
standard arm, a total number of 134 patients is required.
All parameters will be evaluated in an explorative or
descriptive manner, providing means, medians, ranges,
standard deviations and/or confidence intervals. If p val-
ues are calculated (e.g. in subgroup comparisons or across
treatment arms), they will be presented explicitly without
referring to hypotheses or a significance level. Usually, no
error adjustment for multiple testing will be performed.
Thus the p values will reflect the comparison-wise error
and not the experiment-wise error. All p values will be
two-sided if not otherwise stated. The statistical methods
described in this section are suited for the data and distri-
butions usually expected in this type of trials. The suitabil-
ity will be checked after data entry. If necessary, the
statistical method will be modified accordingly. Feasibil-
ity, toxicity and other event rates at pre-specified time
points are calculated, providing confidence intervals. In
case of comparison between patient groups, these rates
will be analyzed by Fisher's exact test, χ2 test or Mantel-
Haenszel test (or trend test according to Cochran/Armit-
age), respectively. Event related data like relapse-free or
overall survival will be estimated by the product limit
method by KAPLAN and MEIER and compared using the
logrank test. If the Peto logrank test is not appropriate
because of violation of the proportional hazard assump-
tion, Gehan's generalization of the Wilcoxon rank sum
test for censored data will be applied. If appropriate, prog-BMC Cancer 2007, 7:77 http://www.biomedcentral.com/1471-2407/7/77
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nostic strata will be taken into account. The methods
mentioned above are likewise suitable for the univariate
evaluation of prognostic factors. Multivariate analyses
may be performed by suitable regression models (COX
proportional hazard regression model, logistic regres-
sion).
Patient selection
In order to be included in the TREAT trial, patients are
required to have histopathologically confirmed diagnosis
of non-small cell lung cancer (NSCLC), pathologic stage
IB, IIA, IIB or T3N1 (without need for further radiother-
apy). Tumor had to be resected completely without
detectable residual tumor including negative margins
(R0) and systematic intraoperative dissection of mediasti-
nal lymph nodes according to the guidelines of the British
thoracic society had to be performed [21]. All accessible
hilar and mediastinal lymph nodes should be removed
for pathologic evaluation. Study drug administration
should only be administered to patients with full recovery
after surgery and is to begin on d28 to d42 postopera-
tively. Histological tumor types which are eligible are
squamous cell carcinoma, adenocarcinoma (including
adenocarcinomas with bronchioloalveolar differentia-
tion), large cell carcinoma (excluding tumors with slight
areas of small cell carcinoma) and mixed cell carcinoma
without small cell fraction.
The following inclusion criteria are required: Provision
of informed consent according to local regulatory require-
ments for participation in the study, Age = 18 years; < 75
Years, Karnofsky Performance Status ≥ 80% or ECOG ≤ 1,
adequate hematological laboratory parameters (Hemo-
globin ≥ 10 g/dl, ANC ≥ 1500/μl, Platelets ≥ 100000/μl),
adequate hepatic laboratory parameters (Bilirubin ≤ 1.5 ×
UNL, ASAT/ALAT ≤ 2 × UNL), adequate renal laboratory
parameters (Creatinine ≤ 1,5 mg/dl and calculated Creat-
inine Clearance ≥ 60 ml/min). Furthermore cardiac func-
tion allowing cisplatin chemotherapy (in case of doubt
echocardiography is mandatory documenting LVEF >
49%), electrocardiogram without significant cardiac
arrhythmia, FEV1 ≥ 1.2 l post-operatively, respiratory
function not impeding cisplatin-based chemotherapy
assessed by either absolute DLCO or capillary/arterial
BGA in resting condition (absolute DLCO > 40 % or pO2
> 60 mmHg in resting condition), agreement by the
patient to use an effective method of contraception, nega-
tive pregnancy test for women of childbearing potential
unless they are postmenopausal at baseline (postmeno-
pausal women must have been amenorrheic at least for 12
months to be considered of non childbearing potential).
Patients are not eligible with the presence of a Pancoast
tumor, involvement of N2/N3 lymph nodes and/or dis-
tant metastases. The following histological tumor types
are excluded: pure bronchioloalveolar carcinoma, mixed
cell carcinoma with small cell fractions, large cell carci-
noma with areas of small cell carcinoma. Further exclu-
sion criteria are pregnancy or lactation period, other co-
existing malignancies or malignancies diagnosed within
the last 5 years with the exception of a CIS of the cervix or
non-melanomatous skin cancer, radio- and/or chemo-
therapy within the last five years, concurrent administra-
tion of any other antitumor therapy, non-compliance
with vitamin (folic acid and vitamin B12) intake or to
whom administration is not possible, hypersensitivity to
pemetrexed or to any of the excipients of Alimta™, to cis-
platin or to any other platinum compound and/or to
vinorelbin or to any other vinca-alkaloid. Patients who
have previously completed or been withdrawn from this
study or any other study with the respective medication in
this study, have had treatment with an investigational
new drug, currently or within the last 30 days, and/or par-
ticipation in another clinical trial, currently or during the
last 12 weeks, and/or previous participation in this study,
history of a psychological illness or condition such as to
interfere with the patient's ability to understand the
requirements of the study, with any clinically significant
disease that in the opinion of the investigator is likely to
put the patient at risk or to interfere with the evaluation of
the patient's safety and of the study outcome (this
includes, but is not limited to: clinically significant cardiac
disease [e.g. congestive heart failure, symptomatic coro-
nary artery disease and cardiac arrhythmia not well con-
trolled with medication] or myocardial infarction within
the last 6 months, uncontrolled hypertension, interstitial
pneumonia or extensive or symptomatic interstitial fibro-
sis of the lung, pleural effusion or ascites, which cause res-
piratory compromise), a history or presence of any CNS
disorder or psychiatric disability judged by the investiga-
tor to be clinically significant and/or interfering with com-
pliance, a serious concomitant systemic disorder (e.g.
active infection including HIV) that in the opinion of the
investigator would compromise the patient's ability to
complete the study, post-operative complications or other
surgery-related conditions that could interfere with a
study participation, hearing function/tinnitus impeding
chemotherapy with cisplatin and/or vinorelbine, alcohol
and/or drug abuse, inability to interrupt high dose sali-
cylates (like aspirin) or other non-steroidal anti-inflam-
matory drugs (NSAID's) for a 5-day period starting 2 days
before administration of Pemetrexed (8-day period for
long-acting agents such as piroxicam) and patients with
organ allografts, neurologic disorders and who cannot be
regularly observed for psychological, sociological or geo-
graphical reasons or other concomitant conditions not
permitting adequate follow-up and compliance to the
protocol are not eligible. Patients with sero(pneumo)-
thorax after pneumonectomy or lobectomy will not beBMC Cancer 2007, 7:77 http://www.biomedcentral.com/1471-2407/7/77
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excluded. Those patients must be monitored for toxicity
closely for any other active or uncontrolled infection.
Work-up
The following assessments will be performed before, dur-
ing and after the study (Table 2). Optimal preoperative
staging should have consisted of the following procedures
and should have been assured at least in a time interval
starting 28 days prior to surgery: CT scan of the thorax and
abdomen including adrenal glands and the right lower
liver margin (in case adrenal glands are not available fur-
ther CT scan of the abdomen is mandatory; if only right
lower liver margin is not available assessment by either CT
scan of abdomen or abdominal ultrasound should be per-
formed), MRT (preferably) or CT scan of the skull and
bone scintigraphy (if a FDG-PET scan has been performed
bone scintigraphy can be omitted). Not more than 14
days prior to the start of chemotherapy, for all patients the
following baseline parameters will be assessed: patient
demography, clinical examination including physical
examination, height, weight, vital signs, Karnofsky or
ECOG Performance Status, assessment of the neurological
status, existing signs and symptoms, medical history
(including concurrent illnesses) and specific details on the
diagnosis of non-small cell lung cancer (NSCLC), previ-
ous anti-cancer therapy and their outcome, concomitant
medication, laboratory assessment including hematologi-
cal parameters (hemoglobin, WBC, ANC, platelets), elec-
trolytes (Na, K, Ca), hepatic parameters (total bilirubin,
ASAT, ALAT, AP, gGT, LDH), renal parameters (creatinine,
calculated creatinine clearance, Urea, uric acid), coagula-
tion parameters (Quick, PTT, Fibrinogen), and pregnancy
test for women with childbearing potential. Furthermore
chest-X-ray, electrocardiography and optional echocardi-
ograph (mandatory only in case of doubt whether cardiac
function allows cisplatin chemotherapy) will be per-
formed. Pulmonary function will be assessed by FEV1,
vital capacity and total capacity and by either absolute
DLCO or capillary/arterial BGA in resting condition with
absolute DLCO > 40 % or pO2 > 60 mmHg in resting con-
dition. Patients with clinical suspicion of altered hearing
capability or symptoms, e.g. tinnitus, should undergo fur-
ther evaluation by audiometry. If preoperative staging had
not comprised all mandatory procedures it should be
completed as outlined above before registration.
Every patient must provide a written informed consent to
the trial procedures. The patient must be informed ver-
bally and by the provided patient information by the
investigator, or a person designated by the investigator if
permitted by local regulations, before informed consent is
obtained.
Study phase
In an initial study phase of 4 months of patient enroll-
ment, 36 patients (i.e. 18 in each treatment arm) will be
accrued to confirm feasibility. In the second step, further
patients will be recruited up to a total number of 134 (i.e.
67 cases per treatment arm).
Period of Adjuvant Chemotherapy
A cycle is a treatment period of 21 days for Pemetrexed
and Cisplatin (Arm A) or 28 days for Vinorelbine and Cis-
platin (Arm B). Study drug administration is to begin on
d28 to d42 after R0 resection of the tumor and within 14
days after randomization.
Arm A : Pemetrexed and Cisplatin combination
For patients in arm pemetrexed/cisplatin, folic acid (350–
1000 μg) must be given daily beginning approximately 5–
7 days prior to first dose of pemetrexed and continuing
daily until 3 weeks after the last dose of study therapy.
Vitamin B12 (1000 μg) will be administered as an intra-
muscular injection approximately 1 to 2 weeks prior to
first dose of pemetrexed and repeated approximately every
9 weeks until 3 weeks after the last dose of study therapy.
Dexamethasone (4 mg of oral or equivalent) given twice
daily should be taken on the day before, the day of, and
the day after each dose of pemetrexed, for rash prophy-
laxis unless medically contraindicated. Patients must
receive pemetrexed at day 1 at the dose of 500 mg/m2 as
an IV infusion over approximately 10 minutes. Beginning
30 minutes after the end of the pemetrexed infusion, cis-
platin at a dose of 75 mg/m2 should be administered IV
over approximately 60 minutes. Each institution should
provide adequate hydration with cisplatin treatment,
according to local habits and the approved package insert
of cisplatin, and similarly in both treatment arms. A cycle
is a treatment period is 21 days; a total of four cycles is
intended.
Arm B: Vinorelbine and Cisplatin combination
Patients in arm vinorelbine and cisplatin follow the regi-
men as in the published phase III adjuvant study [8]: IV
vinorelbine at the dose of 25 mg/m2 in combination with
cisplatin at a dose of 50 mg/m2 at day 1, followed by the
same schedule with IV vinorelbine at the dose of 25 mg/
m2 in combination with cisplatin at a dose of 50 mg/m2
at day 8. Vinorelbine will be repeated on days 15 and 22
at the dose of 25 mg/m2. The scheduled infusion time is
6–10 minutes for vinorelbine and approximately 60 min-
utes for cisplatin. Each institution should provide ade-
quate hydration with cisplatin treatment, according to
local habits and the approved package insert of cisplatin,
and similarly in both treatment arms. A cycle is a treat-
ment period is 28 days; a total of four cycles is intended.BMC Cancer 2007, 7:77 http://www.biomedcentral.com/1471-2407/7/77
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During the chemotherapy the following assessments will
be performed (Table 2): clinical examination including
physical examination, neurologic assessment, weight,
vital signs, Karnofsky or ECOG Performance Status at the
beginning of each cycle, hematological laboratory assess-
ment (hemoglobin, WBC, ANC, platelets) at least once
weekly. At the start of each cycle (3 days prior to or at least
at day 1), laboratory assessment including hematological
parameters (hemoglobin, WBC, ANC, platelets), electro-
lytes (Na, K, Ca), hepatic parameters (total bilirubin,
ASAT, ALAT, AP, LDH), renal parameters (Urea, uric acid,
creatinine, calculated creatinine-clearance), compliance,
concomitant medication and adverse events will be
recorded. In case of suspicious findings a relapse of dis-
ease has to be confirmed by further imaging.
Toxicity management
Toxicities are classified by grade, type, duration, onset,
and relationship to study treatment according to CTCAE
version 3.0.
After application of chemotherapy blood count should be
performed at least once weekly. In case of leukocytopenia
or neutrocytopenia CTC grade 4 (leukocytes < 1.0 × 109/
L), antibiotic prophylaxis according to local habits is rec-
ommended. Prophylaxis should be used similarly in both
treatment arms. Routine use of colony-stimulating factor
(CSF) is not permitted during this study. ASCO guidelines
for use of CSF should be followed [22]. Granulocyte col-
ony stimulating factor must have been discontinued at
least 24 hours prior to the start of the next chemotherapy
infusion. In case of infection in neutropenia or occurrence
of fever of unknown origin, further diagnostic procedures
should be performed and antibiotic treatment according
to the criteria of the German Paul-Ehrlich-Gesellschaft
should be initiated [23]. In case of thrombocytopenia
CTC grade 4 the patient will be discontinued from the
study. In the event of CTC Grade 3 or 4 diarrhea, the fol-
lowing supportive measures are allowed: hydration, octre-
otide, and antidiarrheals. If diarrhea is severe (requiring
intravenous rehydration) and/or associated with fever or
severe neutropenia (Grade 3 or 4), broad-spectrum antibi-
otics must be prescribed. Patients with severe diarrhea or
any diarrhea associated with severe nausea or vomiting
must be hospitalized for intravenous hydration and cor-
rection of electrolyte imbalances. Patients with CTC grade
3 or 4 diarrhea will be discontinued from the study. Pro-
fessional supervised oral care protocols that include
patient education in an attempt to reduce the severity of
mucositis from chemotherapy is highly advised to all
patients. In case of mucositis related pain, symptomatic
therapy according to WHO guidelines should be per-
formed. Based on their proposed mechanisms, antimicro-
bial agents, such as combined polymyxin E, tobramycin,
and amphotericin or single-agent iseganan, appear to
have no associated mechanistic rationale for the preven-
tion of mucositis and probably could provide benefit only
for patients with late-stage ulcerative mucositis, in which
bacterial superinfection occurs. The use of amphotericin
suspension at clinical signs of mucosal soor and at
mucositis Grad 3/4 is recommended. For patients receiv-
ing pemetrexed leucovorin should be considered. Patients
with CTC grade 3 or 4 mucositis will be discontinued
from the study.
Dose adjustments, safety and discontinuation of treatment
The dose reductions are limited to a preset pattern, and
eliminate the need to make any calculations or resolve
conflicting recommendations if two or more toxicities
occur within the same cycle. It also ensures that therapeu-
tic chemotherapy doses will be administered in all treat-
ment cycles.
Patients should be instructed to report any toxicity that
occurs during drug administration of each treatment
course and in the period between cycles.
Treatment will be modified in case of hematological and/
or non-hematological toxicities. All dose adjustments will
be made according to the system showing the greatest
degree of toxicities. Toxicities will be graded according to
the NCI Common Toxicity criteria (CTCAE version 3.0).
No dose re-escalation will be performed after dose reduc-
tion. If the study treatment cannot be administered after
an additional 2 weeks delay because of any toxicity, it
should be definitively discontinued.
On day 1 of each cycle either in arm A or in arm B, the fol-
lowing criteria have to be met for the administration of
both cisplatin and pemetrexed or vinorelbine, respec-
tively: ANC = 1,500/μl, Platelets = 100,000/μl, Serum cre-
atinine < 1,5 mg/dl and calculated creatinine clearance =
60 ml/min, no other grade = 2 toxicity (except for clini-
cally non-relevant AEs such as alopecia, altered taste, nau-
sea, vomiting). If these criteria are not met, drug
administration has to be delayed up to 1 week to allow for
recovery. If a delay of more than 14 days due to toxicity is
necessary, the patient is to be discontinued from the
study.
On day 8 for the administration of both cisplatin and
vinorelbine, the following criteria have to be met : ANC =
1,500/μl, Platelets = 100,000/μl, Serum creatinine < 1.5
mg/dl and creatinine clearance = 60 ml/min, Bilirubin <
1.5 × UNL. If these criteria are not met, drug administra-
tion has to be delayed up to 1 week to allow for recovery.
If a delay of more than 14 days due to toxicity is necessary,
the patient is to be discontinued from the study.BMC Cancer 2007, 7:77 http://www.biomedcentral.com/1471-2407/7/77
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On day 15 and 22 of each cycle, the following criteria have
to be met for the administration of vinorelbine (according
to [8]): Neutrophils (ANC) = 1,500/μl, Platelets =
100,000/μl, Bilirubin < 1.5 × UNL, no other grade = 2 tox-
icity (except for clinically non-relevant AEs such as alo-
pecia, vomiting, nausea, altered taste). If these criteria are
not met, Vinorelbine administration is omitted at that
day, and treatment with Vinorelbine will be resumed on
day 22 or together with Cisplatin in the following next
cycle, respectively.
Dose adjustments according to hematological toxicity at
the start of a subsequent course of the therapy will be
based on platelet and neutrophil nadir counts from the
preceding cycle of therapy. No dose modifications will be
made for anemia. ANC must be = 1,500/μl and platelets =
100,000/μl as outlined above prior to the start of any
cycle. Treatment may be delayed to allow sufficient time
for recovery. Upon recovery patients should be re-treated
using the guidelines as outlined in table 1.
Any patient experiencing Grade 3/4 non-hematological
toxicity (except for nausea/vomiting/hair loss) associated
with therapy will be discontinued from the study.
In case of neurological and/or hearing CTC grade 2 toxic-
ity, administration should be delayed and reassessed one
week later. If toxicity has resolved at least to grade 1 ther-
apy should be continued with 50% dose reduction for cis-
platin for further administrations. In case of decrease of
calculated creatinine clearance, despite adequate hydra-
tion, administration has to be delayed and reassessed one
week later and if the value of creatinine clearance remains
< 60 ml/min, patient has to be discontinued.
For patients who develop clinically significant pleural or
peritoneal effusions (on the basis of symptoms or clinical
examination) during therapy, consideration should be
given to drain the effusion prior to therapy. Though, if, in
the investigator's opinion, the effusion represents relapse
and/or progression of disease, the patient should be dis-
continued from study therapy. However, disease relapse
has to be confirmed by adequate imaging methods.
Patients with sero(pneumo)-thorax after hemi-pneumon-
ectomy or lobectomy will not be excluded. Those patients
must be monitored for toxicity closely.
Dose reductions for hepatic dysfunction will be based on
bilirubine and/or transaminase values. For bilirubin val-
ues 1.5–3 × UNL and ASAT/ALAT < 5 × UNL, vinorelbine
has to be reduced to 50%. For Grade 3/4 hepatic toxicity
the patient has to be discontinued from study.
Premature Withdrawal
Patients have the right to withdraw from the study at any
time for any reason. The investigator also has the right to
withdraw patients from the study in the event of intercur-
rent illness, adverse events, protocol violations, adminis-
trative reasons or other reasons. Discontinuation of a
patient should be based upon one of the objective toxicity
criteria. The following reasons can lead to premature with-
drawal from therapy of a patient: major protocol viola-
tion, Non-compliance of a patient with protocol
procedures, unacceptable toxicity according to the proto-
col, unacceptable toxicity as perceived by the patient
(refusal to continue), withdrawal of consent by the
patient, lost to follow-up, pregnancy, medical decision by
the investigator, appropriate evaluation demonstrates
recurrence of disease. The reason for withdrawal of a
patient needs to be documented and the study coordinat-
ing center has to be informed immediately. Patients who
have been withdrawn from therapy will have to be further
documented for follow-up.
Surgery
Surgery will be performed prior to chemotherapy. The sur-
gical principles follow the guidelines of oncologic surgery.
The tumor and all intrapulmonary lymphatic drainage
must be removed completely, employing lobectomy or
pneumonectomy or complex resections, if necessary. En
bloc resection of closely adjacent or invaded structures is
preferential to a discontinuous resection. Resection mar-
gins should be assessed by frozen section analysis when-
ever possible; this includes bronchial, vascular and other
margins with close proximity to the tumor if necessary to
obtain radical resection. Re-excision is preferred whenever
possible, if positive resection margins are encountered. To
achieve uncomplicated bronchus- and trachealhealing
stump or anastomoses (sleeve resection) can be covered
with viable tissue (pedicled pleural, pericardial, intercos-
tal muscle flap or others). Considering the criteria of func-
tional operability, the aim is to obtain R0-resection. All
accessible hilar and mediastinal lymph nodes should be
removed for pathologic evaluation, using the technique of
mediastinal lymph node dissection. Technique of medias-
tinal lymph node dissection is recommended according to
the guidelines of the British Thoracic Society [21,24].
Lymph nodes are to be identified and properly labelled by
the surgeon. Tumor infiltration of lymph nodes may not
be apparent and is recommended to be diligently sought.
Microscopic assessment is required to accurately deter-
mine the N-status and should be performed as described
in [25]. Complete mediastinal lymph node dissection is
defined as when all tissue containing lymph nodes is
removed at all levels accessible within the operation.
Reflecting lymph node involvement, R0-resection is
defined by the absence of tumor infiltration in the most
distal lymph node level removed according to [26]. If pos-BMC Cancer 2007, 7:77 http://www.biomedcentral.com/1471-2407/7/77
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sible, the most distant level should be the upper-paratra-
cheal lymph nodes (Level 2). The natural course of a
developing sero(pneumo)-thorax in case of pneumonec-
tomy or lobectomy is not regarded as a exclusion criteria.
However, patients must be followed up closely for devel-
oping toxicities.
Radiotherapy
Radiotherapy is not planned.
Maintenance Therapy and Follow Up Period
No maintenance therapy is allowed. Follow-up visits are
planned starting at 30 days after the end of the last chem-
otherapy cycle and afterwards in 3 monthly intervals for
the first 2 years. In the 3rd year patients will be followed up
in 6 monthly intervals (Table 2).
The follow up visits comprise clinical examination includ-
ing physical examination, neurologic assessment, weight,
vital signs, Karnofsky or ECOG Performance Status, labo-
ratory assessment including hematological parameters
(hemoglobin, WBC, ANC, platelets), hepatic parameters
(total bilirubin, ASAT, ALAT, AP, LDH), chest X-ray, with
further examinations in case of clinical symptoms, to con-
firm relapse by imaging techniques, abdominal ultra-
sound (optional; left to the discretion of the participating
center. Center must have determined follow up procedure
with abdominal ultrasound before initiation of the study
in the center), concomitant medication. Additional
assessments in the 1st follow up at 30 days after the end of
the last chemotherapy cycle comprise assessment of FEV,
of vital and total capacity, capillary or arterial BGA under
resting conditions, absolute DLCO and adverse events.
Further examinations in case of clinical symptoms to con-
firm relapse by imaging techniques
Trial duration
Individual participation is completed either three years
after enrolment or death of the patient. Duration of the
study is about 4 years, 6 months
Discussion
Definitive surgery has been the mainstay of therapy of
patients with early stage non-small cell lung cancer. Out-
come in this group of patients was improved by adminis-
tering adjuvant chemotherapy with systemic platinum-
based chemotherapy regimens [7-10]. However, the com-
bination of cisplatin and vinorelbine resulted in rates of
grade 3/4 neutropenia of around 75%, rates of febrile neu-
tropenia of up to 12.5% and rates of treatment related
death of 1–2%. Up to 77% of the patients had at least one
dose reduction or omission and 55% required one dose
delay or more, most related to neutropenia. Only about
50 % of patients randomized on the combination of cis-
platin and vinorelbine received the intended dose of
vinorelbine (dose reduction mainly due to toxicity) and
only 50% of patients completed all four cycles of chemo-
therapy [8,9,12]. Particularly patients who underwent
pneumonectomy were more likely to fail chemotherapy
than patients with lesser extent of resection. Those
patients completed chemotherapy only in 41% of cases
(OR 0.34; 95% CI 0.17–0.68) [12]. These patients mainly
discontinued therapy due to toxicity, with statistically sig-
nificant more frequently grade 3/4 toxicities than in
patients with lesser extent of surgery. Reasons for discon-
tinuation of chemotherapy were mainly patient refusal
combined with toxicity while disease progression or inter-
current illness were uncommon reasons [12]. One has to
consider that relevant toxicities are associated with poor
compliance and are still a major issue in clinical trials of
adjuvant therapy. Furthermore one has to take into
account, that toxicity especially in patients with lung
resection for lung cancer might be even more critical than
in patients under adjuvant treatment for other cancers.
First of all due to the resection of the lung, where the
occurrence of pneumonia is a severe complication – par-
ticularly after pneumonectomy, which was performed in
24–37% of patients in the adjuvant trials. Second, with a
median age of 60–65 and most patients presenting with
chronic obstructive lung disease the risk of pneumonia
after resection, particularly after pneumonectomy should
be reduced as far as possible. Therefore it seems reasona-
ble to test a less toxic regimen also in early stages after R0
resection of the tumor, where reduced toxicities might
improve the feasibility of drug delivery, compliance and
the convenience of treatment for the patient and hence
perhaps survival. Pemetrexed shows clear activity in non-
small cell lung cancer [13] and has demonstrated efficacy
Table 1: Dose modifications according to hematological toxicity in previous cycle
Platelets (× 109/L) Nadir ANC (× 109/L) Nadir Percent or previous dose (both drugs)
≥ 50 and ≥ 0.5 100 %
≥ 50 and < 0.5 75%
< 50 and Any 50%
Any and < 1.0 + fever of = 38.5°Ca 75%
Recurrence of CTC Grade 3 or 4 after 2 dose 
reductions
Recurrence of CTC Grade 3 or 4 after 2 dose 
reductions
Discontinue patient from study
a these criteria meet the CTCAE version 3.0 (NCI 2003) definition of febrile neutropeniaB
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) Table 2: Flow chart study procedures
Adjuvant Chemotherapy Phase
Pre-study 
Phase
Pre-study
Phase
Cycle 1 Cycle 2 Cycle 3 Cycle 4 1st follow 
up (30 
days after 
end of 
chemo-
therapy)
Further Follow-Up
Treatment Arm A B A B A B A B A B A &B
Timeframe (days) -28 prior to 
Surgery
-14 prior to 
Chemotherapy 
start
1–21 1–28 22–42 29–56 43–63 57–84 64–84 85–112 114 142 until 3 years after CTX
day of visit -28 prior to 
Surgery
-14 prior to 
Chemotherapy 
start
1 1, 8, 15, 22 22 29, 36, 43, 50 43 57, 64, 71, 78 64 85, 92, 99, 106 114 142 starting 3 month after 1st follow up in Years 1 & 2:
3-monthly, then 6-monthly
Informed Consent X
Demography X
Pregnancy test X1
Medical history, Signs and symptoms X
Neurological Status X X X X X
Clinical Examination2 X2 X2 X2 X2 X2 X2 X2
Concomitant medication X X X X X X X
Laboratory hematology X X3,4 X3,4 X3,4 X3,4 XX
Laboratory hepatic X X4 X4 X4 X4 XX
Laboratory renal X X4 X4 X4 X4
Laboratory electrolytes X X4 X4 X4 X4
Laboratory coagulation X
12-lead ECG X
Assessment of LVEF9 X
Chest-X-ray X X5 X5
Abdomen ultrasound X6 X10 X10
MRT or CT skull X
CT6 lower liver marginliver X
Assessment of vital/total capacity X X
Assessment of FEV1 X X
Assessment of absolute DLCO or 
BGA under resting conditions
X X
Bone Scintigraphy7 X
Audiometry8 X
Compliance X X X X X
Adverse events X X X X X X
Follow-Up tumor assessment5 XX
1 in women with child-bearing potential
2 Clinical examination including physical examination, neurologic assessment, height (height only to be assessed at baseline), weight, vital signs, Karnofsky or ECOG Performance Status at the beginning of each chemotherapy cycle.
3 hematology parameters, including Hb, platelets, WBC, ANC at least once weekly during chemotherapy phase
4 Three days prior to or at least at day 1 of each chemotherapy-cycle
5 Relapse of disease should be confirmed by imaging techniques
6 CT scan of the thorax and abdomen including adrenal glands and the right lower liver margin (in case adrenal glands are not available further CT scan of the abdomen is mandatory; if only right lower liver margin is not available assessment by 
either CT scan of abdomen or abdominal ultrasound should be performed)
7 If a FDG-PET scan has been performed, bone scintigraphy can be omitted
8 Optional; patients with clinical suspicion of altered hearing capability or symptoms should undergo further evaluation by audiometry
9 Echocardiography optional, mandatory only in case of doubt whether cardiac function allows Cisplatin chemotherapy
10 optional, left to the discretion of the center prior to study initiation of the centerBMC Cancer 2007, 7:77 http://www.biomedcentral.com/1471-2407/7/77
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in combination regimes similar to other standard plati-
num doublets [14-18]. The combination of platin and
pemetrexed can be easily delivered, is well tolerated and
only results in a 25% rate of grade 3/4 neutropenia and -
in vitamin supplemented patients- the incidence of febrile
neutropenia was < 1%. Dose reductions occur only in 2–
4% of the patients and dose delivery of the intended
pemetrexed and platin dose is excellent with dose deliver-
ies of pemetrexed up to 95% [13,14,19]. Considering
these issues there is a legitimate hope that side-effects can
be minimized and that the therapy might at least be equi-
effective in comparison to the chemotherapy regimens
used so far. Thus, this treatment could become an option
for patients with NSCLC in the adjuvant setting.
Abbreviations
AE adverse event
ANC absolute neutrophil count
AUC area under the concentration time curve
BGA blood gas analysis
CT computed tomography
DLCO diffusion capacity for carbon monoxide
FDG-PET 18F-fluorodeoxyglucose-Positron emission
tomography
FEV1 Forced expiratory volume in one second
i.m. intramuscular
MRT Magnetic resonance tomography
NSAID Non-steroidal anti-inflammatory drug
NSCLC Non-small cell lung cancer
TLC Total lung capacity
UNL Upper Normal Limit
VC Vital capacity
WBC white blood cell count
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